Effective therapy with tranexamic acid in a case of chronic disseminated intravascular coagulation with acquired α2-antiplasmin deficiency associated with AL amyloidosis

Giuseppe Colucci; Lorenzo Alberio; Maximilian Jahns; Peter Keller; Simon Steiner; Ilka Rüsges-Wolter; Bernhard Lämmle

doi:10.1160/TH09-04-0248

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2009; 102(06): 1285-1287
DOI: 10.1160/TH09-04-0248

Letters to the Editor

Schattauer GmbH

Effective therapy with tranexamic acid in a case of chronic disseminated intravascular coagulation with acquired α2-antiplasmin deficiency associated with AL amyloidosis

Authors

Giuseppe Colucci

¹Department of Haematology and Central Haematology Laboratory, Bern University Hospital, Inselspital and University of Bern, Bern, Switzerland
Lorenzo Alberio

¹Department of Haematology and Central Haematology Laboratory, Bern University Hospital, Inselspital and University of Bern, Bern, Switzerland
Maximilian Jahns

¹Department of Haematology and Central Haematology Laboratory, Bern University Hospital, Inselspital and University of Bern, Bern, Switzerland
Peter Keller

¹Department of Haematology and Central Haematology Laboratory, Bern University Hospital, Inselspital and University of Bern, Bern, Switzerland
Simon Steiner

¹Department of Haematology and Central Haematology Laboratory, Bern University Hospital, Inselspital and University of Bern, Bern, Switzerland
Ilka Rüsges-Wolter

¹Department of Haematology and Central Haematology Laboratory, Bern University Hospital, Inselspital and University of Bern, Bern, Switzerland
Bernhard Lämmle

¹Department of Haematology and Central Haematology Laboratory, Bern University Hospital, Inselspital and University of Bern, Bern, Switzerland

Abstract

Full Text

References

References
1 Mumford AD, O'Donnell J, Gillmore JD. et al. Bleeding symptoms and coagulation abnormalities in 337 patients with AL-amyloidosis. Br J Haematol 2000; 110: 454-460.
2 Gamba G, Montani N, Anesi E. et al. Clotting alterations in primary systemic amyloidosis. Haematologica 2000; 85: 289-292.
3 Zangari M, Elice F, Fink L. et al. Hemostatic dysfunction in paraproteinemias and amyloidosis. Semin Thromb Hemost 2007; 33: 339-349.
4 Taylor Jr. FB, Toh CH, Hoots WK. et al. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost 2001; 86: 1327-1330.
5 Dalton SO, Johansen C, Mellemkjaer L. et al. Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study. Arch Intern Med 2003; 163: 59-64.
6 Meyer K, Williams EC. Fibrinolysis and acquired alpha-2 plasmin inhibitor deficiency in amyloidosis. Am J Med 1985; 79: 394-396.
7 Takahashi H, Koike T, Yoshida N. et al. Excessive fibrinolysis in suspected amyloidosis: demonstration of plasmin-alpha 2-plasmin inhibitor complex and von Willebrand factor fragment in plasma. Am J Hematol 1986; 23: 153-166.
8 Liebman HA, Carfagno MK, Weitz IC. et al. Excessive fibrinolysis in amyloidosis associated with elevated plasma single-chain urokinase. Am J Clin Pathol 1992; 98: 534-541.
9 Medved L, Nieuwenhuizen W. Molecular mechanisms of initiation of fibrinolysis by fibrin. Thromb Haemost 2003; 89: 409-419.
10 Takahashi T, Suzukawa M, Akiyama M, et al. Systemic AL amyloidosis with disseminated intravascular coagulation associated with hyperfibrinolysis. Int J Hematol 2008; 87: 371-374.